SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
Loading market information…
HKSE · 1609.HK · HKD
Stock price
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Star Sports Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 82.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Star Sports Medicine Co., Ltd. manufactures and markets clinical products and solutions for sports medicine in China. The company offers medical implant, such as bioabsorbable suture anchor, includes all-suture anchor, PEEK suture anchor, and carbon fiber reinforced PEEK suture anchor; interference screws and sheath fixation system, bioabsorbable interference screw, bioabsorbable interference screws and sheath fixation system, PEEK screws and sheath fixation system, and PEEK composite interference screw; suture buttons and high-strength sutures, such as adjustable suture button, fixed suture button, ultra-high molecular weight polyethylene(UHMWPE) suture; meniscus repair systems, all-suture meniscus repair system, accurFix all-inside meniscus repair system, and multi-needle and flexible meniscus repair system. The surgical equipment and associated medical consumables, includes plasma RF ablation equipment, arthroscopic surgical shaver, arthroscopic camera system, and disposable shaver blade plasma electrode. Its other products includes disposable PRP preparation kit, desktop centrifuge. The company also provides biomaterial platform, imaging and dynamic platform, intelligent medicine platform, and tissue engineering platform. The company was founded in 2017 and is headquartered in Beijing, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:05 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.01-CN¥0.88 (-0.62%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.2% below the high.
CN¥48.46-CN¥0.16 (-0.33%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.39% below the high.
HK$50.70+HK$0.05 (+0.1%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.37% below the high.
CN¥181.75+CN¥2.75 (+1.54%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
HK$32.36-HK$0.72 (-2.18%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 26.82% below the high.
HK$44.48-HK$0.58 (-1.29%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.31% below the high.
HK$4.56+HK$0.07 (+1.56%)
AK Medical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.22% below the high.
HK$3.77-HK$0.15 (-3.83%)
Peijia Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 48.85% below the high.
